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Summary
Background: Several hospital-based investigations have reported that a high proportion of
patients with heart failure (HF) have preserved left ventricular ejection fraction (LVEF). The
purpose of this study was to determine the prevalence, prognosis, and predictors for mortality
of Japanese HF patients with preserved versus reduced LVEF in a prospective cohort fashion.
Methods and results: Our hospital-based database including inpatients and also outpatients was
used for analysis. Out of 4255 new patients, 597 patients (male/female 414/183, age 65.1± 12.9
years) were diagnosed as having symptomatic HF at the initial visit. Among 589 HF patients
undergoing echocardiography, 398 (67.6%) showed a preserved LVEF (>50%) and 191 (32.4%) had
a reduced LVEF (≤50%). Patients with preserved LVEF were older (p = 0.004) and more likely to be
female (p = 0.002). During follow-up of an average 539 days, 34 cardiovascular deaths occurred,
and patients with preserved LVEF showed a better prognosis than those with reduced LVEF (3.2%
vs. 7.4% per year, p = 0.0097). Multivariate Cox hazards analysis identiﬁed LVEF as an indepen-
dent predictor in all HF patients. Also, separated group analysis showed that presence of chronic
kidney disease was independently associated with poor prognosis irrespective of HF types.
∗ Corresponding author at: The Cardiovascular Institute, Roppongi 7-3-10, Minato-ku, Tokyo 106-0032, Japan. Tel.: +81 3 3408 2151;
fax: +81 3 3401 0469.
E-mail address: ayumi-go@cvi.or.jp (A. Goda).
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Conclusions: This prospective cohort study identiﬁed prevalence and prognosis of HF in Japanese
in- and outpatients, where patients with preserved LVEF showed a better prognosis than those
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and reduced LVEF. The endpoints included cardiovascu-
lar mortality. In the present study, cardiovascular death
was deﬁned as mortality from acute myocardial infarction,with reduced LVEF.
© 2009 Japanese College of C
Introduction
After years of focus on heart failure (HF) arising from
reduced left ventricular ejection fraction (LVEF), there has
been a recent growth in interest in the syndrome of HF
associated with preserved LVEF. Several community-based
and hospital-based studies have reported that a high pro-
portion of patients with HF have preserved LVEF [1—11].
Several previous studies report lower mortality rates of 8%
in these patients, compared with 19% to over 50% annual
mortality in patients with reduced LVEF [1—3,6—10,12—16].
These and other studies are often considered to provide clin-
ical evidence that the prognosis for patients with preserved
LVEF is more benign [10,17], although some studies report
no difference in the risk of death [1,2,13].
The epidemiology of HF in Japan should be quite dif-
ferent from that in Western countries in respect of ethnic
background and etiology. However, there are few Japanese
hospital-based reports about preserved LVEF [8,18,19], and
the prevalence and prognosis of HF with preserved LVEF
are not well known. The purpose of the present study was
to determine the prevalence, prognosis, and predictors for
mortality of HF patients in both inpatients and outpatients,
with preserved versus reduced LVEF in a prospective cohort
fashion.
Methods
Study patients
A prospective observational, hospital-based cohort study of
the Shinken Database was conducted to investigate the mor-
tality and morbidity of cardiovascular diseases in Japan.
The design of the Shinken Database has been described in
a previous report [20]. The database comprises details on
all of the new patients, including both inpatients and out-
patients, who visited The Cardiovascular Institute Hospital
between April 2004 and March 2006 (n = 4255). Patients were
excluded if they had cancer that was not cured, or they were
foreigners. The Cardiovascular Institute Hospital is located
in a downtown area in Tokyo, Japan. In the present study,
HF patients were deﬁned as those with symptomatic HF
[New York Heart Association (NYHA) classes II—IV] coexis-
tent with structural heart diseases, which were diagnosed
using cardiovascular examinations, including echocardiog-
raphy, nuclear scanning, and angiography.
Data collectionIn each patient, after obtaining echocardiogram and chest
X-ray, evaluation of cardiovascular status was performed
using echocardiography, exercise test, 24-h Holter record-
h
p
o
mology. Published by Elsevier Ireland Ltd. All rights reserved.
ngs, and blood laboratory data according to the attending
hysicians’ decision within 3 months after the ﬁrst visit.
n the present study, the following information has been
ollected as the initial clinical parameters: gender, age,
ody mass index (BMI), drug information, coexisting con-
itions including hypertension, atrial ﬁbrillation, diabetes
ellitus, and hyperlipidemia. In most of the patients, the
ollowing echocardiographic parameters were also collected
ncluding left ventricular diameter of diastole, left ventric-
lar diameter of systole, thickness of the interventricular
eptum (IWSth), thickness of the posterior wall (PWth),
nd LVEF using M-mode echocardiography. Patients were
ivided into two categories according to the values of LVEF:
‘preserved’’ (LVEF > 50%) or ‘‘reduced’’ (LVEF≤ 50%) LVEF
roup. Left ventricular (LV) hypertrophy was deﬁned by
chocardiography (IWSth or PWth≥ 13mm). Chronic kid-
ey disease (CKD) is deﬁned as glomerular ﬁltration rate
GFR)≤ 60ml/min−1/1.73 cm2 according to the National
idney Foundation and American Heart Association guide-
ines, or as requiring regular hemodialysis [21]. GFR was
stimated using the 4-component Modiﬁcation of Diet in
KD (MDRD) equation, incorporating age, race, sex, and
erum creatinine level: eGFR = 186× (serum creatinine level
mg/dl])−1.154 × (age ([in years])−0.203 × 1.233 [22,23]. For
omen, the product of this equation was multiplied by a
orrection factor of 0.742.
Ischemic heart disease was considered present if the
atients had one of the followings: (1) a documented history
f myocardial infarction, angina, or prior coronary revascu-
arization; (2) pathologic Q waves on the electrocardiogram;
r (3) greater than 75% stenosis in one or more coronary
rteries on coronary angiograms. Valvular heart disease was
eﬁned as long-standing mitral or aortic valve involvement
hich should be documented by physical examination and
chocardiography, angiography, or history of surgical repair.
diopathic dilated cardiomyopathy was diagnosed by the
resence of global LV dilatation with impaired systolic func-
ion occurring in the absence of known cardiac causes.
ypertrophic cardiomyopathy was diagnosed by echocardio-
raphy when hypertrophy (IWSth or PWth > 12mm) without
ypertension was present.
rimary objective
he primary objective of the present study was to assess
he mortality of Japanese HF patients both with preservedeart failure, stroke, or sudden death, which was unex-
ected death from a cardiovascular cause in the absence
f progressive circulatory failure lasting for 60min or
ore.
1 A. Goda et al.
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Figure 1 Cardiovascular mortality stratiﬁed by left ventric-
ular ejection fraction (LVEF). Kaplan—Meier survival curves
stratiﬁed by LVEF. Vertical axis shows the survival rate at follow-
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econdary objective
he secondary objective was to assess the role of clinical
haracteristics of the patients on mortality. Univariate and
ultivariate analyses were performed to determine risk fac-
ors for the mortality of HF patients with all the clinical
ariables obtained at the initial visit.
ollow-up
ital status was assessed by interrogation of the hospital
nformation system. In case of patients followed by other
ospitals, it was assessed by letter and/or phone.
tatistical analysis
n the characteristics of study patients, consecutive vari-
bles were compared between two groups using unpaired
-test. Proportion of patients was compared using chi-square
est. Data (except percentages) are presented as mean± SD.
tatistical signiﬁcance was set at p < 0.05. The survival
ates were estimated using the Kaplan—Meier method and
og-rank tests were used for group comparisons. The Cox
roportional hazards models were employed to estimate
azard ratios for mortality using SPSS (SPSS Inc., Chicago, IL,
SA) for Windows (Microsoft Corp., Redmond, WA, USA), ver-
ion 11.0 software. Although the univariate models included
ll the clinical variables at the initial visit, the adjustment by
ultivariate models was performed with parameters deter-
ined as signiﬁcant in the univariate ones.
thical issues
he Ethical Committee in the Cardiovascular Institute
ranted ethical permission for this study and the patients
ave written informed consent.
esults
atient characteristics
mong 4255 patients who visited our hospital because
f clinical reasons, 597 patients (male/female 414/183,
ge 65.1± 12.9 years) were diagnosed as presenting with
ymptomatic HF. In the 589 patients (99.3%) that had under-
one echocardiography, average LVEF was 56.2± 18.0%:
91 patients (32.4%) with systolic dysfunction (LVEF≤ 50%)
nd 398 patients (67.6%) with preserved systolic function
LVEF > 50%). The characteristics of the study patients are
hown in Table 1. Patients with preserved LVEF were older
66.0± 12.1 years vs. 62.8± 14.1 years, p = 0.004), more
ikely to be female (34.9% vs. 22.0%, p = 0.002), more likely
o have lower presence of CKD (29.9% vs. 49.7%, p < 0.001),
nd had a higher rate of ischemic heart disease (54.3% vs.
4.5%, p = 0.026). There were no signiﬁcant differences in
he prevalence of hypertension (36.9% vs. 33.0%, p = 0.360),
iabetes (22.6% vs. 26.7%, p = 0.303), hyperlipidemia (28.6%
s. 25.7%, p = 0.255), atrial ﬁbrillation (27.6% vs. 26.2%,
= 0.767), and LV hypertrophy (8.8% vs. 12.6%, p = 0.114).
he proportion of outpatients tended to be higher in the
l
F
l
o
tp (0—1.0) and horizontal axis, follow-up period (0—1200 days).
he solid line represents the survival rate in reduced LVEF and
he dotted line, that in preserved LVEF. *Log-rank test.
reserved LVEF group than in the reduced LVEF group,
ecause admission within 3 months after ﬁrst visit due to
ardiovascular events was more frequently observed in the
atter (36.7% vs. 44.0%, p = 0.054). The preserved LVEF group
ad a lower prevalence of NYHA III and IV consistent with
he admission rate, which indicated that the reduced LVEF
roup in this cohort included patients with more severe HF
equiring hospitalization than those with preserved LVEF.
ccordingly, prescription rates of diuretics, nitrate, digi-
alis, and angiotensin-converting enzyme inhibitors among
hose with reduced LVEF were higher than among those with
reserved LVEF. The clinical characteristics in inpatients and
utpatients are shown in Table 2 . In the outpatients group,
atients with preserved LVEF were signiﬁcantly older and
ore likely to be female, while in the inpatients group,
his did not reach statistical signiﬁcance, however, the same
endency was observed. Available laboratory ﬁndings in 542
atients at the initial visit are shown in Table 3. Averaged B-
ype natriuretic peptide (BNP) in patients with preserved
VEF was signiﬁcantly lower than that in patients with
educed LVEF (269.2± 408.0 pg/dl vs. 641.9± 773.5 pg/dl,
< 0.001).
ortality
uring the mean follow-up period of 539± 257 days, 40 total
eaths and 34 cardiovascular deaths occurred. Of these, 19
atients died of progression of HF, 9 patients of sudden car-
iac death, 6 patients of acute myocardial infarction, and
patients of other reasons without cardiovascular causes.
mong the reduced LVEF group, 18 total deaths and 17 car-
iovascular deaths occurred, while 22 total deaths and 17
ardiovascular deaths occurred among the preserved LVEF
roup. Overall, patients with preserved LVEF showed a bet-
er prognosis than reduced LVEF (3.2% vs. 7.4% per year,
og-rank test, p = 0.0097). The survival curves are shown in
ig. 1. The ﬁgure, at the same time, indicates remarkably
ow mortality of Japanese HF patients compared with that
f HF patients in Western countries, irrespective of the sys-
olic function. Adjusted survival curve is shown in Fig. 2.
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Table 1 Characteristics of the study patients.
Characteristics Reduced LVEF (n = 191) Preserved LVEF (n = 398) p-Value
Age (years) 62.8± 14.1 66.0± 12.1 0.004
Female gender 42 (22.0%) 139 (34.9%) 0.002
BMI 23.4± 4.6 23.1± 3.8 0.459
Hypertension 63 (33.0%) 147 (36.9%) 0.360
Atrial ﬁbrillation 50 (26.2%) 110 (27.6%) 0.767
Hyperlipidemia 49 (25.7%) 114 (28.6%) 0.255
Diabetes 51 (26.7%) 90 (22.6%) 0.303
CKDa 95 (49.7%) 119 (29.9%) <0.001
LV hypertrophyb 24 (12.6%) 35 (8.8%) 0.114
History of myocardial infarction 61 (31.9%) 72 (18.1%) <0.001
LVEF (%) 33.6± 10.4 67.1± 8.0 <0.001
Admission ratec 84 (44.0%) 146 (36.7%) 0.054
Underlying cardiovascular diseases
Ischemic heart disease 85 (44.5%) 216 (54.3%) 0.026
Valvular heart disease 61 (31.9%) 149 (37.4%) 0.192
Idiopathic dilated cardiomyopathy 56 (29.3%) 1 (0.3%) <0.001
Hypertrophic cardiomyopathy 17 (8.9%) 7 (1.8%) <0.001
Other cardiovascular diseases 12 (6.3%) 53 (13.3%) 0.011
NYHA class <0.001
II 126 (66.0%) 342 (85.9%)
III 43 (22.5%) 42 (10.6%)
IV 22 (11.5%) 14 (3.5%)
Medications
Nitrate 71 (37.2%) 194 (48.7%) 0.003
Diuretics 107 (56.0%) 125 (31.4%) <0.001
-Blockers 74 (38.7%) 158 (39.7%) 0.395
Angiotensin-receptor blockers 79 (41.4%) 128 (32.2%) 0.024
Statins 47 (24.6%) 121 (30.4%) 0.070
Calcium-channel blockers 24 (12.6%) 93 (23.4%) 0.001
Angiotensin-converting enzyme inhibitors 47 (24.6%) 49 (12.3%) <0.001
Digitalis 41 (21.5%) 43 (10.8%) 0.001
BMI, body mass index; CKD, chronic kidney disease; LV, left ventricular; LVEF, left ventricular ejection fraction; NYHA, New York Heart
Association.
ickne
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ca Estimated glomerular ﬁltration rate <60ml/min/1.73 cm2.
b LV hypertrophy; thickness of the interventricular septum or th
c Admission rate: admission within 3 months after the ﬁrst visit.
After adjusting for age, gender, proportion of outpatients,
presence of CKD, and NYHA classes, the survival curves
were signiﬁcantly different in the two groups (p = 0.0032).
Among the inpatients, patients with preserved LVEF showed
a better prognosis than those with reduced LVEF (5.6% vs.
12.9% per year, log-rank test, p = 0.0480), while among the
outpatients, prognosis in patients with preserved LVEF and
reduced LVEF was comparable (1.3% vs. 1.9% per year, log-
rank test, p = 0.1650). In terms of inpatients, the prognosis
of our patients is comparable to prognosis in Japanese HF
patients previously reported.
Risk factors for prognosisUnivariate Cox hazard analysis showed that older age [haz-
ard ratio (HR) 1.09; CI: 1.05—1.12, p < 0.001), female gender
(HR 2.63; CI: 1.34—5.15, p = 0.005), lower BMI (HR 0.93;
CI: 0.87—0.99, p = 0.047), presence of CKD (HR 9.10; CI:
a
e
3
C
tss of the posterior wall >12mm.
.77—21.99, p < 0.001), hospital admission within 3 months
fter the ﬁrst visit (HR 2.24; CI: 1.13—4.43, p = 0.021),
-blocker use (HR 0.27; CI: 0.10—0.07, p = 0.007), statin
se (HR 0.32; CI: 0.11—0.91, p = 0.032), and presence of
educed LVEF (HR 2.37; CI: 1.21—4.64, p = 0.012) were sig-
iﬁcantly associated with the cardiovascular death of the
tudy population (Table 4). Multivariate Cox hazards anal-
sis identiﬁed reduced LVEF as an independent prognostic
actor for cardiovascular deaths. The results of univariate
nalysis in each of preserved and reduced LVEF group are
hown in Table 4. The predictors of cardiovascular death
n reduced LVEF included older age, female gender, pres-
nce of CKD, and presence of ischemic heart disease. In
ontrast, the predictors of mortality in preserved LVEF were
ge, presence of atrial ﬁbrillation, LV hypertrophy, and pres-
nce of CKD. Therefore, presence of LV hypertrophy (HR
.21; CI 1.05—9.86, p = 0.041) and atrial ﬁbrillation (HR 3.15;
I 1.22—8.16, p = 0.018) were related to mortality only in
he preserved LVEF group. Multivariate Cox hazards analysis
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Table 2 Characteristics of the inpatients and outpatients.
Characteristics Inpatients (n = 230) Reduced LVEF (n = 84) Preserved LVEF (n = 146) p-Value
Age (years) 66.3± 13.2 64.9± 14.8 67.2± 12.2 0.217
Female gender 74 (32.2%) 23 (27.4%) 51 (34.9%) 0.151
BMI 23.5± 4.6 23.4± 5.3 23.5± 4.1 0.875
Hypertension 99 (43.0%) 33 (39.3%) 66 (45.2%) 0.232
Atrial ﬁbrillation 59 (25.7%) 23 (27.4%) 36 (24.7%) 0.380
Hyperlipidemia 96 (41.7%) 32 (38.1%) 64 (43.8%) 0.239
Diabetes 72 (31.3%) 28 (33.3%) 44 (30.1%) 0.359
CKDa 95 (41.3%) 49 (58.3%) 46 (31.5%) <0.001
LV hypertrophyb 23 (10.0%) 13 (15.5%) 10 (6.8%) 0.032
LVEF (%) 53.9± 19.0 32.2± 10.8 66.5± 8.6 <0.001
Underlying cardiovascular diseases
Ischemic heart disease 158 (68.7%) 48 (57.1%) 110 (75.3%) <0.001
Valvular heart disease 52 (22.6%) 20 (23.8%) 32 (21.9%) 0.431
Idiopathic dilated cardiomyopathy 23 (10.0%) 22 (26.2%) 1 (0.7%) <0.001
Hypertrophic cardiomyopathy 7 (3.0%) 5 (6.0%) 2 (1.4%) 0.063
NYHA class <0.001
II 156 (67.8%) 36 (42.9%) 312 (86.9%)
III 45 (19.6%) 28 (33.3%) 17 (11.6%)
IV 29 (12.6%) 20 (23.8%) 9 (6.2%)
Medications
Nitrate 134 (58.3%) 40 (47.6%) 94 (64.4%) 0.010
Diuretics 100 (43.5%) 57 (67.9%) 43 (29.5%) <0.001
-Blockers 106 (46.1%) 39 (46.4%) 67 (45.9%) 0.523
Angiotensin-receptor blockers 90 (39.1%) 41 (48.8%) 49 (33.6%) 0.016
Statins 95 (41.3%) 28 (33.3%) 67 (45.9%) 0.042
Calcium-channel blockers 59 (25.7%) 12 (14.3%) 47 (32.2%) 0.002
Angiotensin-converting enzyme inhibitors 60 (26.1%) 31 (36.9%) 29 (19.9%) 0.004
Digitalis 33 (14.3%) 18 (21.4%) 15 (10.3%) 0.018
Outpatients (n = 359) Reduced LVEF (n = 107) Preserved LVEF (n = 252) p-Value
Age (years) 64.1± 12.6 61.1± 13.4 66.0± 12.1 0.003
Female gender 107 (29.8%) 19 (17.8%) 88 (34.9%) 0.001
BMI 23.0± 3.7 23.4± 3.9 22.9± 3.6 0.280
Hypertension 111 (30.9%) 30 (28.0%) 81 (32.1%) 0.261
Atrial ﬁbrillation 101 (28.1%) 27 (25.2%) 74 (29.4%) 0.254
Hyperlipidemia 67 (18.7%) 17 (15.9%) 50 (19.8%) 0.234
Diabetes 69 (19.2%) 23 (21.5%) 46 (18.3%) 0.283
CKDa 119 (33.1%) 46 (43.0%) 73 (29.0%) 0.007
LV hypertrophyb 39 (10.9%) 13 (12.1%) 26 (10.3%) 0.366
LVEF (%) 57.7± 17.1 34.8± 10.0 67.5± 7.6 <0.001
Underlying cardiovascular diseases
Ischemic heart disease 143 (39.8%) 37 (34.6%) 106 (42.1%) 0.113
Valvular heart disease 158 (44.0%) 41 (38.3%) 117 (46.4%) 0.097
Idiopathic dilated cardiomyopathy 34 (9.4%) 34 (31.8%) 0 (0%) <0.001
Hypertrophic cardiomyopathy 17 (4.7%) 12 (11.2%) 5 (2.0%) <0.001
NYHA class 0.172
II 312 (86.9%) 90 (84.1%) 222 (88.1%)
III 40 (11.1%) 15 (14.0%) 25 (9.9%)
IV 7 (1.9%) 2 (1.9%) 5 (2.0%)
Medications
Nitrate 131 (36.6%) 31 (29.0%) 100 (39.7%) 0.025
Diuretics 132 (36.9%) 50 (46.7%) 82 (32.5%) 0.010
-Blockers 126 (35.2%) 35 (32.7%) 91 (36.1%) 0.269
Angiotensin-receptor blockers 117 (32.7%) 38 (35.5%) 79 (31.3%) 0.291
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Table 2 (Continued ).
Outpatients (n = 359) Reduced LVEF (n = 107) Preserved LVEF (n = 252) p-Value
Statins 73 (20.4%) 19 (17.8%) 54 (21.4%) 0.235
Calcium-channel blockers 58 (16.2%) 12 (11.2%) 46 (18.3%) 0.055
Angiotensin-converting enzyme inhibitors 36 (10.1%) 16 (15.0%) 20 (7.9%) 0.040
Digitalis 51 (14.2%) 23 (21.5%) 28 (11.1%) 0.011
BMI, body mass index; CKD, chronic kidney disease; LV, left ventricular; LVEF, left ventricular ejection fraction; NYHA, New York Heart
Association.
a Estimated glomerular ﬁltration rate <60ml/min/1.73 cm2.
b LV hypertrophy; thickness of the interventricular septum or thickness of the posterior wall >12mm.
Table 3 Laboratory data of the patients.
Variablesa Reduced LVEF (n = 174) Preserved LVEF (n = 368) p-Value
Albumin (g/dl) 3.76 ± 0.54 3.95 ± 0.51 <0.001
Blood urea nitrogen (mg/dl) 23.8 ± 14.6 17.9 ± 8.3 <0.001
eGFR (ml/min/1.73 cm2) 54.4 ± 24.7 64.9 ± 20.3 <0.001
Creatinine (ml/min) 1.6 ± 2.1 0.9 ± 1.1 <0.001
Urinary albumin (mg/dl) 6.6 ± 2.1 5.9 ± 1.5 0.739
Total cholesterol (mg/dl) 186.4 ± 42.4 194.5 ± 37.1 0.029
Na (mequiv./L) 140.0 ± 3.6 140.6 ± 2.7 0.067
K (mequiv./L) 4.3 ± 0.6 4.2 ± 0.4 0.044
Hemoglobin (g/dl) 13.0 ± 2.3 13.0 ± 1.8 0.800
BNP (pg/ml)b 641.9 ± 773.5 269.2 ± 408.0 <0.001
BNP, b-type natriuretic peptide; eGFR, estimated glomerular ﬁltration
a Variables except for BNP were derived from 542 patients.
b BNP was derived from 386 patients.
in each group (Table 5) identiﬁed that the presence of
CKD was an independent prognostic factor for cardiovascu-
lar deaths in both groups, while ischemic etiology and age
were independent predictors in reduced and preserved LVEF
groups, respectively. When the patients with pure valvular
heart disease were excluded from the Cox hazard analysis
and Kaplan—Meier analysis, the results for risk factors were
almost the same as the total cohort.
Figure 2 Adjusted cardiovascular mortality stratiﬁed by left
ventricular ejection fraction (LVEF). Adjusted Kaplan—Meier
survival curves stratiﬁed by LVEF. Vertical axis shows the sur-
vival rate at follow-up (0—1.0) and horizontal axis, follow-up
period (0—1200 days). The solid line represents the survival rate
in reduced LVEF and the dotted line, that in preserved LVEF.
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iscussion
ajor ﬁndings
he major ﬁndings of the present study were as follows: (1)
F with preserved LVEF accounted for about 68% of all the
F in- and outpatients visiting a cardiovascular hospital in
apan between 2004 and 2005; (2) our study patients with
reserved LVEF showed a better prognosis than reduced LVEF,
nd reduced LVEF was an independent predictor for mortal-
ty when inpatients and outpatients were combined; (3) in
he preserved LVEF group, age and presence of CKD were
ndependent predictors for poor prognosis.
revalence of preserved HF patients
previous study suggested that the prevalence of HF with
reserved LVEF has been increasing over time in Western
ountries [24]. Although the prevalence of preserved LVEF
aried according to the difference in age, race, and the
ut-off value of LVEF, there is a widespread agreement
hat preserved LVEF accounted for more than one third of
otal patients admitted with HF [1—11]. In the recent study
rom Tsuchihashi et al., the prevalence of preserved LVEF
ccounted for one third of total admitted HF patients [19].
n our study, the prevalence of preserved LVEF among HF
atients accounted for 67.6% and those patients included
wo thirds of total inpatients, which was somewhat higher
han that of previous reports. Although it may be partly
114
Table 4 Risk factors for cardiovascular mortality in heart
failure patients from univariate and multivariate Cox
analysis.
Variables Hazard ratio (95% CI) p-Value
Univariate
Age 1.09 (1.05—1.12) <0.001
Female 2.63 (1.34—5.15) 0.005
BMI 0.93 (0.87—0.99) 0.047
Hypertension 0.74 (0.35—1.54) 0.738
Hyperlipidemia 0.41 (0.16—1.06) 0.065
Diabetes 1.47 (0.70—3.07) 0.308
CKD 9.10 (3.77—21.99) <0.001
Ischemic heart disease 1.73 (0.86—3.50) 0.118
Valvular heart disease 1.06 (0.52—2.14) 0.880
Atrial ﬁbrillation 1.52 (0.75—3.07) 0.246
LV hypertrophy 0.98 (0.65—4.35) 0.283
Admission within 3
months
2.24 (1.13—4.43) 0.021
Reduced LVEF 2.37 (1.21—4.64) 0.012
Nitrate use 1.19 (0.60—2.39) 0.618
Diuretics use 1.26 (0.63—2.55) 0.515
-Blockers use 0.27 (0.10—0.70) 0.007
Angiotensin-receptor
blockers use
0.60 (0.27—1.33) 0.209
Statin use 0.32 (0.11—0.91) 0.032
Calcium-channel
blockers use
0.69 (0.27—1.80) 0.452
Angiotensin-converting
enzyme inhibitors
use
1.74 (0.78—3.89) 0.176
Digitalis use 0.89 (0.31—2.54) 0.826
Multivariate
Age 1.06 (1.02—1.09) 0.001
Female 2.42 (1.21—4.84) 0.013
CKD 5.51 (2.20—13.82) <0.001
Admission within 3
months
1.53 (0.76—3.10) 0.238
Reduced LVEF 2.15 (1.08—4.30) 0.030
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hypertension, and diabetes, but that ischemic heart dis-BMI, body mass index; CI, conﬁdential intervals; CKD, chronic
kidney disease; LV, left ventricular; LVEF, left ventricular ejec-
tion fraction.
ttributed to the fact that our cohort included HF outpa-
ients, the present results could draw more attention to this
ighly prevalent status of HF with preserved LVEF in Japan.
atient backgrounds
atients with preserved LVEF are known to be older, are
ore often women, more frequently have hypertension, and
ess frequently have ischemic heart disease [1,2,6—11,13].
he rate of diabetes and atrial ﬁbrillation are thought to
e similar between preserved and reduced LVEF. According
o recent reports from Japan, similar background dif-
erences could be applied to Japanese HF patients in
oth inpatient-based and community-based cohorts [18,19].
ctually, the differences in patient’s backgrounds in our
tudy were almost identical to those of previous reports,
e
i
p
sA. Goda et al.
n that patients with preserved LVEF tended to be older
nd were more likely to be women. However, our study
ound that patients with preserved LVEF had lower rates of
ypertension and higher rates of ischemic heart disease. In
ach inpatient/outpatient group, the same tendencies were
bserved. This might be derived from the fact that previ-
us cohorts differed from our cohort in patient enrollment.
herefore, it should be noted that our study has clariﬁed the
urrent status of HF with preserved LVEF in all the patients
isiting a cardiovascular hospital including outpatients. In
ddition, our hospital is located in the center of a metropoli-
an city, Tokyo, and is a cardiovascular specialized hospital,
nd many patients in our hospital are transferred from other
ospitals. This might mean that the number of patients with
ypertensive heart disease (only 14 patients) was few in our
ohort, and they might be usually followed by other hospi-
als.
rognosis
t has long been unclear whether HF patients with pre-
erved LVEF have a prognosis similar to patients with reduced
VEF. Smith et al. and Solomon et al. reported that progno-
is of preserved LVEF was signiﬁcantly better than that of
educed LVEF [10,25]. However, Senni et al. revealed that
here was no signiﬁcant difference between the mortality in
he patients with preserved and reduced LVEF [13]. Recent
eports in 2006 have revealed that there is no signiﬁcant dif-
erence between the two groups [1,2]. In Japan, a previous
tudy has reported that there were no signiﬁcant differences
n prognosis among three groups divided by their LVEF [8,19].
n the contrary, our present study found that the progno-
is of preserved LVEF was signiﬁcantly better than that of
educed LVEF, even if limited to inpatients. This apparent
iscrepancy should be understood under the difference in
nrollment criteria, which should result in differences in
atient backgrounds and HF severity including NYHA class.
dditionally, the prognosis in our study is very good com-
ared with that reported in previous studies in Japan. When
he prognosis was limited to the inpatient group, the prog-
osis was similar with that in a previous report in Japan [19],
hich suggested the prognosis in outpatients would be good.
ndependent risk factors for mortality
everal factors have been considered to affect the mor-
ality of HF patients, including older age, severity of HF
26,27], anemia, presence of CKD [28—30], higher BNP
31—33], and lower LVEF [34]. Actually, among the total
ohort of the present study, all these clinical variables could
e determined as signiﬁcant risk factors for mortality as is
onsistent with previous studies. However, little informa-
ion is available whether these signiﬁcant predictors can be
pplied to both preserved and reduced LVEF. Owan et al.
eported that the predictors in preserved and reduced LVEF
ere similar, including age, serum creatinine, hemoglobin,ase and year of admission are signiﬁcant predictors only
n reduced LVEF [1]. Bhatia et al. also showed that the
redictors in the two groups were similar, including age,
ystolic blood pressure, the presence of peripheral vascu-
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Table 5 Risk factors for cardiovascular mortality in heart failure patients from univariate and multivariate Cox analysis.
Variables Reduced LVEF Variables Preserved LVEF
Hazard ratio (95% CI) p-Value Hazard ratio (95% CI) p-Value
Univariate Univariate
Age 1.06 (1.02—1.11) 0.002 Age 1.12 (1.07—1.18) <0.001
Female 4.29 (1.65—11.14) 0.003 Female 2.20 (0.85—5.70) 0.105
BMI 0.95 (0.86—1.05) 0.323 BMI 0.92 (0.83—1.01) 0.069
Hypertension 0.86 (0.30—2.45) 0.778 Hypertension 0.68 (0.24—1.93) 0.471
Diabetes 1.26 (0.66—1.26) 0.660 Diabetes 1.53 (0.54—4.36) 0.423
Hyperlipidemia 0.33 (0.08—1.44) 0.139 Hyperlipidemia 0.50 (0.14—1.75) 0.280
Atrial ﬁbrillation 0.63 (0.18—2.18) 0.460 Atrial ﬁbrillation 3.15 (1.22—8.16) 0.018
LV hypertrophy 0.49 (0.06—3.66) 0.483 LV hypertrophy 3.21 (1.05—9.86) 0.041
LVEF 0.99 (0.95—1.04) 0.673 LVEF 0.98 (0.92—1.04) 0.441
CKD 5.23 (1.50—18.20) 0.009 CKD 11.84 (3.40—41.20) <0.001
Ischemic heart disease 4.03 (1.31—12.36) 0.008 Ischemic heart disease 0.95 (0.37—2.45) 0.908
Valvular heart disease 0.71 (0.23—2.18) 0.710 Valvular heart disease 1.57 (0.61—4.07) 0.358
Admission within 3 months 2.39 (0.88—6.46) 0.086 Admission within 3 months 1.90 (0.73—4.93) 0.186
Multivariate Multivariate
Age 1.03 (0.99—1.06) 0.120 Age 1.09 (1.03—1.15) 0.002
Female 1.23 (0.43—3.55) 0.699 Atrial ﬁbrillation 2.50 (0.95—6.54) 0.063
ey dis
C
T
p
L
L
J
A
W
o
RIschemic heart disease 3.48 (1.13—10.70) 0.029
CKD 5.18 (1.48—18.10) 0.010
BMI, body mass index; CI, conﬁdential intervals; CKD, chronic kidn
lar disease, hyponatremia, dementia, and presence of CKD
[2]. At the same time, the predictors among reduced LVEF
included presence of cirrhosis, while the predictors among
preserved LVEF included presence of cancer, dialysis, ane-
mia, and the respiratory rate. In our study, presence of CKD
is a common risk factor both in preserved and reduced LVEF.
Otherwise, the impact of many factors including LV hypertro-
phy and atrial ﬁbrillation differed between the reduced and
preserved LVEF groups by univariate analysis. Consequently,
ischemic etiology and advanced age had different effects
on mortality by multivariate analysis. Therefore, our study
also supported the notion that different factors should be
paid more attention to, according to reduced or preserved
LVEF.
Limitations
The present study has several limitations: (1) it was based
on a single-center experience, and therefore it might be
difﬁcult to apply the results to all Japanese HF patients;
(2) the observation period was short in view of the long
lives of Japanese HF patients; (3) LVEF was obtained by
using only M-mode echocardiography, which might overes-
timate the value of LVEF in some patients; and (4) the
proportion of patients treated with optimal drugs estab-
lished in HF was lower in the present study than that of other
studies, although the drug information was collected only
during the ﬁrst 3 months after the initial visit. Nevertheless,
the present study identiﬁed the prevalence and mortal-
ity of Japanese HF inpatients/outpatients in a prospective
and hospital-based cohort fashion, thus providing important
information for decision-making in managing Japanese HF
patients.LV hypertrophy 1.64 (0.53—5.14) 0.394
CKD 6.07 (1.66—22.18) 0.006
ease; LV, left ventricular; LVEF, left ventricular ejection fraction.
onclusions
his prospective cohort study identiﬁes prevalence and
rognosis of HF patients, where the patients with preserved
VEF showed a better prognosis than those with reduced
VEF, and provides a basis for therapeutic management in
apan.
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